Every guide, in one place.

The week-1 food playbook for GLP-1 users when nothing sounds good. Practical moves that keep nausea down and protein up.

When appetite drops, protein becomes critical. These are the best options to protect muscle on Ozempic and Wegovy.

A non-peptide pill, 15% weight loss, and potentially much cheaper to manufacture. Why Lilly's orforglipron could restructure the GLP-1 market.

No labs, no long intake, shipped in days. Here's what $199/mo gets you — and what it doesn't.

24% weight loss in Phase 2, three-hormone mechanism, and on track for FDA filing in 2026-2027. Here's what retatrutide actually is and why it matters.

Physician-led, the thorough intake, and real behavioral coaching. Here's what $59/mo + meds actually buys you in 2026.

Flat $99/mo with real insurance navigation and a dietitian. Here's what actually arrived in the mail, what we got wrong, and who it's not for.

How tirzepatide works, why its results are dramatically better than semaglutide, and whether the price makes it the right pick for you.

We signed up for every major telehealth program, tracked the real costs, and ranked them by who you actually are — not by who pays us the most.

Same molecule, two brands, wildly different rules. Here's what actually separates them and what it means for cost, coverage, and who should take which.

The pill finally exists. Here's how it compares on results, price, and who should switch — and who definitely shouldn't.